Markets:

Overview

News

Currencies

International

Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

3.119 +0.949 (+43.72%)

Streaming Delayed Price Updated: 1:37 PM EST, Jan 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday ↗

September 07, 2022

Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.

Via Benzinga

Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 06, 2022

Via ACCESSWIRE

Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase

August 24, 2022

Via ACCESSWIRE

Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket ↗

August 17, 2022

Gainers Hill International, Inc. (NYSE: HIL) shares rose 58.1% to $2.75 in pre-market trading after the company agreed to be acquired by Global Infrastructure Solutions Inc. for $2.85 per share.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 16, 2022

Via Benzinga

Dermata Therapeutics: Q2 Earnings Insights ↗

August 15, 2022

Dermata Therapeutics (NASDAQ:DRMA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 15, 2022

Via ACCESSWIRE

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 01, 2022

Gainers Conformis (NASDAQ:CFMS) shares moved upwards by 13.2% to $0.29 during Monday's after-market session. The company's market cap stands at $53.5 million.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 27, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 26, 2022

Via Benzinga

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday ↗

July 27, 2022

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 07, 2022

Via Benzinga

Tesla, Twitter And 76 Biggest Movers From Friday ↗

July 11, 2022

Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board...

Via Benzinga

Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session ↗

July 01, 2022

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday.

Via Benzinga

This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday ↗

July 08, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 01, 2022

Via Benzinga

Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday ↗

July 05, 2022

Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 01, 2022

Good morning, trader! It's time for another look at the biggest pre-market stock movers as we dive into the latest news for Friday!

Via InvestorPlace

Akebia Therapeutics And 20 Stocks Moving Premarket ↗

July 01, 2022

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday.

Via Benzinga

Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday ↗

July 01, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 30, 2022

Gainers

Via Benzinga

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session ↗

June 30, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical...

Via Benzinga

Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea

June 13, 2022

- Topline results expected in the second half of 2022 -

From Dermata Therapeutics

Via AccessWire

Dermata to Present at the H.C. Wainwright Global Investment Conference

May 23, 2022

SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and...

From Dermata Therapeutics

Via AccessWire

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 16, 2022

Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc....

From Dermata Therapeutics

Via AccessWire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 02, 2022

Via Benzinga

Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

April 25, 2022

SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of...

From Dermata Therapeutics

Via AccessWire

Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

April 21, 2022

SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment...

From Dermata Therapeutics

Via AccessWire

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results

March 28, 2022

DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase...

From Dermata Therapeutics

Via AccessWire

Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference

March 24, 2022

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and...

From Dermata Therapeutics

Via AccessWire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.